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Summary
 
According to current understanding, cytoplasmic events including activation of protease cas-
cades and mitochondrial permeability transition (PT) participate in the control of nuclear apop-
tosis. However, the relationship between protease activation and PT has remained elusive.
When apoptosis is induced by cross-linking of the Fas/APO-1/CD95 receptor, activation of
interleukin-1
 
b
 
 converting enzyme (ICE; caspase 1) or ICE-like enzymes precedes the disrup-
tion of the mitochondrial inner transmembrane potential (
 
DC
 
m
 
). In contrast, cytosolic CPP32/
Yama/Apopain/caspase 3 activation, plasma membrane phosphatidyl serine exposure, and nu-
clear apoptosis only occur in cells in which the 
 
DC
 
m
 
 is fully disrupted. Transfection with the
cowpox protease inhibitor 
 
crmA
 
 or culture in the presence of the synthetic ICE-specific inhib-
itor Ac-YVAD.cmk both prevent the 
 
DC
 
m
 
 collapse and subsequent apoptosis. Cytosols from
anti-Fas–treated human lymphoma cells accumulate an activity that induces PT in isolated mi-
tochondria in vitro and that is neutralized by crmA or Ac-YVAD.cmk. Recombinant purified
ICE suffices to cause isolated mitochondria to undergo PT-like large amplitude swelling and to
disrupt their 
 
DC
 
m
 
. In addition, ICE-treated mitochondria release an apoptosis-inducing factor
(AIF) that induces apoptotic changes (chromatin condensation and oligonucleosomal DNA
fragmentation) in isolated nuclei in vitro. AIF is a protease (or protease activator) that can be
inhibited by the broad spectrum apoptosis inhibitor Z-VAD.fmk and that causes the proteolyt-
ical activation of CPP32. Although Bcl-2 is a highly efficient inhibitor of mitochondrial alter-
ations (large amplitude swelling 
 
1
 
 
 
DC
 
m
 
 collapse 
 
1
 
 release of AIF) induced by prooxidants or
cytosols from ceramide-treated cells, it has no effect on the ICE-induced mitochondrial PT and
AIF release. These data connect a protease activation pathway with the mitochondrial phase of
apoptosis regulation. In addition, they provide a plausible explanation of why Bcl-2 fails to in-
terfere with Fas-triggered apoptosis in most cell types, yet prevents ceramide- and prooxidant-
induced apoptosis.
 
I
 
t is currently assumed that the apoptotic process can be
divided into at least three functionally distinct phases (1–5).
During the heterogeneous initiation phase, cells receive the
death-inducing stimulus via certain receptors such as the
TNF receptor or Fas/APO-1/CD95, shortage of obliga-
tory growth factors, oxygen or metabolic supply, or subne-
crotic physical and chemical damage. The biochemical
events participating in the initiation phase constitute “pri-
vate” pathways in the sense that they depend on the lethal
stimulus. It is only during the subsequent phases that these
initiating events are translated into a regular common pattern
of metabolic reactions. The common pathway can be sub-
divided into an initial effector phase, during which the
“central executioner of apoptosis” is still subject to regula-
tory mechanisms, and a later degradation phase, beyond the
“point of no return”, during which catabolic enzymes be-
come activated in an irreversible fashion. During the degra-
dation phase the morphology and characteristic biochemis-
try of apoptosis (e.g., step-wise DNA fragmentation, and
specific proteolysis of cytoplasmic and nuclear substrates)
become manifest (1–5).
Two nonexclusive mechanisms have been proposed to
intervene as central executioners of the apoptotic effector
phase. On one hand, it appears that apoptosis is associated
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with the critical activation of a family of specific proteases
that include interleukin-1
 
b
 
 converting enzyme (ICE
 
1
 
/
caspase 1), CPP32 (Yama/Apopain/caspase 3), and other
proteases homologous to the 
 
Caenorhabditis elegans
 
 protein
Ced-3 (1–3, 5). On the other hand, the disruption of the
mitochondrial inner transmembrane potential (
 
DC
 
m
 
) marks
a point of no return for the apoptotic cascade (6). More-
over, mitochondria that undergo permeability transition
(PT) or products derived from these organelles induce
chromatin condensation and DNA fragmentation in cell-
free systems of apoptosis (7–11).
Two mitochondrial proapoptotic factors have been puri-
fied: (
 
a
 
) the 15-kD cytochrome 
 
c
 
 protein, which acts to-
gether with cytosolic factors to induce nuclear apoptosis
(10), and (
 
b
 
) a 
 
z
 
50-kD protease that by itself suffices to
cause nuclear apoptosis (11). We have recently shown that
mitochondria release such a 
 
z
 
50-kD apoptogenic protein
(apoptosis-inducing factor, AIF) when they undergo PT (9,
11), a phenomenon that accounts for 
 
DC
 
m
 
 disruption in
intact cells (9, 12, 13) and that is accompanied by the re-
lease of cytochrome 
 
c
 
 (14). The oncoprotein Bcl-2 is an in-
hibitor of PT induced in isolated mitochondria (9, 11),
anucleate cytoplasts (15), and cells (12), underscoring the
idea that PT may indeed constitute a central checkpoint of
the apoptotic cascade. Pharmacological inhibition of PT by
mitochondrion-targeted drugs can inhibit all cytoplasmic
and nuclear manifestations of apoptosis (9, 13, 15), suggest-
ing that PT is a rate-limiting, coordinating step of apopto-
sis. PT is induced by many different physiological effectors
(reactive oxygen species, blockade of the respiratory chain,
changes in the ATP/ADP concentration, pyrimidine nu-
cleotide oxidation, thiol redox potentials, calcium, etc.),
and thus may allow for the convergence of very different
inducers of apoptosis. The multiplicity of PT induction
pathways is underscored by the fact that none of the
known inhibitors of PT, including Bcl-2, can block PT in-
duction in all circumstances (9, 11, 16).
The hierarchical relationship between protease activation
and mitochondrial PT appears complex. The available data
suggest three levels of interaction between proteases and
PT. First, proteases may act upstream of PT. Thus, inhibi-
tors of serine proteases such as 
 
N
 
-tosyl-
 
l
 
-lysyl chlorometh-
ylketone and degenerate tripeptidic inhibitors of ICE-like
proteases such as 
 
N
 
-benzyloxycarbonyl-Val-Ala-Asp.fluo-
romethylketone (Z-VAD.fmk) prevent or retard the gluco-
corticoid-induced 
 
DC
 
m
 
 disruption and subsequent apop-
tosis in thymocytes (13). Second, PT may be regulated
directly by mitochondrial proteases. Thus, calcium- and
prooxidant-induced PT may involve the action of a mito-
chondrial calpain-like protease (17). Third, proteases may
also act downstream of PT. We have recently shown that
the apoptogenic protein (AIF) released from mitochondria
undergoing PT possesses a proteolytic activity that is also
inhibited by Z-VAD.fmk (11).
Prompted by these findings, we have studied the possible
impact of proteases on PT in one prototypic model of apop-
tosis, namely apoptosis induced via ligation of the Fas sur-
face receptor. Fas-mediated cell death is thought to contri-
bute to the maintenance of immune homeostasis, to immune
surveillance of mutating or virus-infected cells, as well as to
the pathological depletion of CD4
 
1
 
 lymphocytes in AIDS
(18, 19). It involves the activation of specific proteases,
namely an ICE-like protease associated with the Fas recep-
tor complex (FLICE/Mach-1/Mch-5/caspase 8; references
20, 21), ICE (caspase 1; references 22–24), and CPP32
(caspase 3; reference 25). Fas-triggered apoptosis is unique
in the sense that it constitutes the only known apoptosis in-
duction pathway that relies on the specific intervention of
ICE (22–24). In addition, Fas-induced apoptosis is not in-
hibited by Bcl-2, at least in some cell types (26–28). This
has lead to the speculation that Fas and Bcl-2 would regu-
late different pathways of apoptosis induction (26–28).
Thus, Fas could trigger an apoptotic pathway that bypasses
the putative Bcl-2/PT checkpoint of the apoptotic effector
phase. Alternatively, it could induce PT in a fashion that is
not controlled by Bcl-2.
In this work, we discriminate between these possibilities
and present evidence indicating that, during Fas-induced
apoptosis, ICE functions as a direct inducer of mitochon-
drial PT. Although Bcl-2 efficiently inhibits mitochondrial
PT induced by a variety of different stimuli including
prooxidants, it completely fails to interfere with ICE-induced
signs of mitochondrial PT including 
 
DC
 
m
 
 disruption and
release of AIF. We show that AIF possesses unique biologi-
cal properties. In addition to its direct apoptotic effect on
isolated nuclei in a cell-free, cytosol-free system, AIF is it-
self an inducer of PT, and thus may be involved in a posi-
tive amplification loop disrupting mitochondrial function.
Moreover, AIF proteolytically activates CPP32, one of the
signature proteases of mammalian cell death. These findings
underscore the implication of mitochondria in the apop-
totic effector phase, provide multiple links between pro-
teases and mitochondrial regulation, and explain the lim-
ited apoptosis-inhibitory effect of Bcl-2. Moreover, our
data suggest a scenario according to which ICE (or ICE-
like proteases), mitochondrial AIF, and CPP32 are sequen-
tially activated and participate in the induction, effector,
and degradation phases of apoptosis, respectively.
 
Materials and Methods
 
Cell Lines and Culture Conditions.
 
Human CEM-C7.H2 lym-
phoma cells were transfected with a PHD1.2 
 
crmA
 
 cDNA (1.46
kb) cloned in the sense orientation into a 
 
b
 
-actin STneo B vector
(crmA cells) or a vector-only control (Neo). Three different
clones hyperexpressing crmA at the protein level yielded similar
functional results. Results are shown for the C7.H2/D1.2/2E8
clone. Alternatively, CEM-C7.H2 cells were transfected with
pEF-tTA 2A10, a doxycyclin-inhibitable transactivator (tTa) and
super-transfected with a tTa-repressed 
 
bcl-2
 
 construct in a tk-Hyg
 
1
 
Abbreviations used in this paper:
 
 
 
DC
 
m
 
, mitochondrial transmembrane po-
tential; AIF, apoptosis-inducing factor; CFS, cell-free system; CMXRos,
cholormethyl-X-rosamine;  ICE, interleukin 1
 
b
 
 converting enzyme;
mClCCP, carbonyl cyanide m-chlorophenylhydrazone; PT, permeability
transition; 
 
t
 
-BHP, ter-butylhydroperoxide. 
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selection vector (pUGD10-3 Bcl-2 tkHyg; reference 29; results
are shown for one out of two clones yielding similar data). Bcl-2
expression was repressed by culture on doxycycline (10 ng/ml, 48 h),
as described (30). Apoptosis was induced by stimulation of 1–5 
 
3
 
10
 
6
 
 cells/ml with the Fas–cross-linking IgM monoclonal antibody
CH-11 (500 ng/ml; Immunotech, Marseille, France) in the pres-
ence or absence of the membrane-permeant–specific inhibitor of
ICE, Ac-YVAD.cmk (100 
 
m
 
M; Bachem, Basel, Switzerland), or
alternatively with C
 
2
 
 ceramide (50 
 
m
 
M; Sigma Chemical Co., St.
Louis, MO).
 
Cytofluorometric Determinations of Apoptosis-associated Alterations
in Whole Cells.
 
To evaluate the 
 
DC
 
m
 
, cells (10
 
6
 
/ml) were incu-
bated with the cationic lipophilic dye chloromethyl-X-rosamine
(CMXRos; 150 nM; Molecular Probes, Inc., Eugene, OR; refer-
ence 15). As a control, cells were simultaneously treated with the
uncoupling agent carbonyl cyanide m-chlorophenylhydrazone
(mClCCP; 50 
 
m
 
M; Sigma Chemical Co.). CMXRos incorpo-
rates into mitochondria driven by the 
 
DC
 
m
 
 (15) and reacts with
thiol residues to form covalent aldehyde-fixable thiol ester bonds
(31). After fixation (4% paraformaldehyde in PBS for 15 min at
room temperature), cells were washed and stained for the detec-
tion of chromatinolysis using the TUNEL method, as described
(31). In one series of experiments, cells were stained with the po-
tential-sensitive dye DiOC
 
6
 
(3) (15 min, 37
 
8
 
C, 40 nM) together
with a biotin–Annexin V conjugate (50 
 
3
 
 dilution; revealed by
streptavidine-phycoerythrine at 5 
 
m
 
g/ml, following the manufac-
turer’s protocol; Boehringer Mannheim GmbH, Mannheim,
Germany), followed by sorting of DiOC
 
6
 
(3)
 
low
 
 Annexin V
 
1
 
,
DiOC
 
6
 
 (3) Annexin V
 
2
 
 and DiOC
 
6
 
(3)
 
high
 
 Annexin V
 
1
 
 cells on
an Elite cytofluorometer (Coulter Corp., Miami, FL), as described
(6, 15).
 
Preparation of Cytosols and Determination of the Activity of ICE-like
Proteases.
 
100 
 
m
 
l cytosols (10
 
7
 
 cells/100 
 
m
 
l in cell-free system
[CFS] buffer [220 mM mannitol, 68 mM sucrose, 2 mM NaCl,
2.5 mM PO
 
4
 
H
 
2
 
K, 0.5 mM EGTA, 2 mM MgCl
 
2
 
, 5 mM pyru-
vate, 0.1 mM PMSF, 1 mM dithiotreitol, 10 mM Hepes-NaOH])
and pH 7.4 buffer (supplemented with additional protease inhibi-
tors: 1 
 
m
 
g/ml leupeptin, 1 
 
m
 
g/ml pepstatin A, 50 
 
m
 
g/ml antipain,
10 
 
m
 
g/ml chymopapain) were prepared by five freeze/thaw cy-
cles in liquid nitrogen, followed by centrifugation (1.5 
 
3
 
 10
 
5
 
 
 
g
 
,
4
 
8
 
C, 1 h) as described (32). The protein concentration in the su-
pernatant was determined by the Bradford assay (Bio Rad Labs.,
Hercules, CA). ICE activity was measured using a fluorogenic
substrate containing the cleavage site YVAD, 4-(4
 
9
 
-deimethyl-
aminophenylazo)  benzoic-YVADAPV-5-(-2-aminoethyl-amino)
naphtalene-1-sulfonic acid (Bachem), as described (22), using a
spectrofluorometer (Kontron SFM 25; Kontron AG, Zurich,
Switzerland). The capacity of cytosols or purified recombinant
human CPP32 activity to cleave the CPP32 recognition site
DEVD was determined using Ac-DEVD-amino-4-methylcou-
marin (Bachem) as fluorogenic substrate (33).
 
Preparation of Organelles.
 
Mitochondria were isolated from
BALB/c hepatocytes (6–8 wk, female) or from different CEM-
C7.H2 lines. Mitochondria were purified on a Percoll
 
Ò
 
 (Pharma-
cia, Uppsala, Sweden) gradient (34) and were stored on ice in
CFS buffer for up to 4 h. Mitochondria were washed and resus-
pended in CFS supplemented with 2 mM ATP. Nuclei from
HeLa cells were purified on a sucrose gradient and conserved in
50% glycerol (Sigma Chemical Co.) in HeLa nuclei buffer at
 
2
 
20
 
8
 
C for a maximum of 15 d, as described (35).
 
Purification of the Mitochondrial AIF.
 
Purified hepatocyte mi-
tochondria were treated with atractyloside (5 mM; Atr; Sigma
Chemical Co.) to induce PT and liberation of AIF (9, 11). Super-
 
natants (150,000 
 
g
 
, 1 h, 4
 
8
 
C) from these mitochondria were con-
centrated on Centricon 10 membranes (
 
>
 
10 kD; Amicon, Bev-
erly, MA) and then injected into a FPLC column (MonoQ
(HR5/5); Pharmacia) preequilibrated with protein-free CFS buf-
fer (see below). Elution was performed on a linear gradient from
0 to 250 mM NaCl at 0.5 ml/min over 30 min, followed by elu-
tion at 1 M NaCl thereafter. All fractionation steps were carried
out at 4
 
8
 
C to avoid loss of biological AIF activity. The active
fraction (eluting at 110 mM NaCl; reference 11) was dialyzed
against protein-free CFS buffer (4
 
8
 
C, overnight, 5,000
 
3
 
 excess of
CFS buffer), concentrated on Centricon 10 membranes, adjusted
to a concentration of 30 
 
m
 
g/ml, and aliquoted to be snap frozen
in liquid nitrogen and stored at 
 
2
 
80
 
8
 
C.
 
Determination of Mitochondrial PT.
 
For the induction of PT,
mitochondria from different cell lines were incubated with cyto-
solic extracts from 
 
a
 
Fas–treated cells (standard dose of 30 
 
m
 
g pro-
tein/ml), purified recombinant ICE (50 
 
m
 
g/ml), the prooxidant
ter-butylhydroperoxide (
 
t
 
-BHP; 30 mM), atractyloside (5 mM;
Sigma Chemical Co.), the protonophore mClCCP (100 ml; Sigma
Chemical Co.), bongkrekic acid (50 mM; provided by Dr. Duine,
Delf University, Delf, The Netherlands), monochlorobiman (30
mM; Sigma Chemical Co.), and/or the calpain inhibitor N-ben-
zyloxycarbonyl-l-leucyl-l-leucyl-l-tyrosine diazomethylketone
(100  mM; Molecular Probes Inc., reference 9). Recombinant ICE
was produced following standard procedures (36) and was al-
lowed to partially (<5%) autoactivate by incubation at 208C for 2 h,
followed by storage on ice for a maximum of 4 h. Two different
consequences of PT were assessed: (a) mitochondrial large ampli-
tude swelling and (b) collapse of the DCm. For determination of
swelling, mitochondria were washed and resuspended in CFS
buffer supplemented with 2 mM ATP at a concentration of 100 mg
mitochondrial protein/10 ml buffer, followed by addition of 90
mM CFS containing 2 mM ATP and recording of adsorption at
540 nm in a spectrophotometer (DU 7400; Beckman Instrs.,
Carlsbad, CA), as described (9). After stabilization of the adsorp-
tion during a minimum interval of 30 s, the indicated substance
was added in a volume of 5 ml. The loss of absorption induced by
5 mM atrectyloside within 5 min was considered 100% of the
large amplitude swelling, as described (9). The DCm was mea-
sured using DiOC6 (3) (40 nM, 15 min at 378C; Molecular
Probes Inc.), after having added the indicated PT inducer (30
min, room temperature). Mitochondria were analyzed in an Elite
cytofluorometer (Coulter Corp.). All DCm determinations were
performed at least three times in each experiment.
Cell-free System of Apoptosis. Nuclei from mouse liver cells
were purified on a sucrose gradient (35), washed two times (1,000 g,
10 min, 48C), and resuspended in CFS buffer. In standard condi-
tions, nuclei (103 nuclei/ml) were cultured in the presence of mi-
tochondrial preparations for 90 min at 378C. Nuclei were stained
with propidium iodide (10 mg/ml; Sigma Chemical Co.) and the
lipophilic dye 5-methyl-bodipy-3-dodecanoic acid (100 nM; Mo-
lecular Probes Inc., reference 37), followed by cytofluorometric
analysis in an analyzer (EPICS Profile II Analyzer; Coulter
Corp.). Only membrane surrounded (5-methyl-bodipy-3-dode-
canoic acid-labeled) particles were gated. A good correlation be-
tween the frequency of nuclei exhibiting chromatin condensation
with 49-6-diamidino-2-phenylindole dihydrochloride (10 mM;
Molecular Probes, Leiden, The Netherlands; reference 38) and
hypoploidy with PI was obtained (Susin, S.A., and G. Kroemer,
manuscript in preparation). DNA fragmentation was determined
by horizontal agarose gel electrophoresis and ethidium bromide
staining as described (9). Electron microscopy of osmium tetrox-
yde-fixed nuclei was performed as described (13).28 Mitochondria and Proteases in Apoptosis
Expression of Human CPP32 and Generation of a Specific Antiserum.
A cDNA encoding human CPP32 was generated by PCR using
the plasmid pKSII-CPP32 (gift from Guy Salvesen, Burnham In-
stitute, La Jolla, CA) as a template and the primers 59-GGAAT-
TCCATATGGAGAACACTGAAAACTCAGTG-39 (forward)
and 59-CCGCTCGAGGTGATAAAAATAGAGTTCTTTTG-
39 (reverse). After digestion with Xho1 and Nde1, this PCR-
generated cDNA was subcloned into pET21b at the Nde1/Xho1
sites to produce CPP32 protein with six histidine resides at its
COOH terminus. Recombinant purified CPP32 was purified as
described (39). New Zealand white female rabbits were injected
subcutaneously with 200 mg of purified CPP32-His6 fusion pro-
tein mixed (1;1 vol/vol) with Freund’s complete adjuvant and
then boosted seven times with 200 mg of protein in Freund’s in-
complete adjuvant before collecting blood and obtaining immune
serum.
Western Blot Analysis. AIF-mediated cleavage of nuclear sub-
strates was determined by the comparative analysis of SDS-PAGE
of HeLa nuclei (5 3 106/lane) cultured in the presence or ab-
sence of supernatant from Atr-treated mitochondria (10 mg pro-
tein/ml, 90 min, 378C) in the presence or absence of Z-VAD.fmk,
as described (11). Western blots of these nuclei were tested for
degradation of poly (ADP-ribose) polymerase (PARP) using the
monoclonal antibody C2-10 (purchased from Guy Poirier, Mon-
treal University, Canada; reference 38). Cleavage of CPP32 in
cells (8 3 105 cells/lane) or in vitro (10 ng recombinant CPP321
10 mg protein of mitochondrial supernatant in 50 ml CFS buffer 6
100 mM Z-VAD.fmk, 15 min at 378C) was determined by using
a polyclonal rabbit antiserum recognizing both CPP32 and the
p17 fragment of proteolytically activated CPP32 (39). Enzymatic
activation of CPP32 (100 ng CPP32 1 variable amounts of mito-
chondrial supernatant in 100 ml CFS buffer 6 100 mM Z-VAD.fmk,
15 min at 378C) was detected by adding 1 mM Ac-DEVD-
amino-4-methylcoumarin (30 min, 378C), as described above. In
one control experiment, Z-VAD.fmk (100 mM) was added to-
gether with Ac-DEVD-amino-4-methylcoumarin.
Results
Fas Cross-linking Provokes Sequential Activation of ICE-like
Proteases, DCm Disruption plus Activation of CPP32, and Nu-
clear Apoptosis. Human CEM-C7.H2 lymphoma cells
can be induced to undergo apoptosis by cross-linking of
Fas. As shown in Fig. 1 A, cells manifest a rapid activation
of protease(s) capable of cleaving a fluorogenic substrate
containing the tetrapeptide YVAD. As described (22, 25),
activation of ICE-like proteases is a rapid process that peaks
15–30 min after Fas cross-linking. It thus precedes the Fas-
induced DCm disruption, as quantified by means of the
DCm-sensitive dye CMXRos. This DCm collapse affects
only a minor fraction of the cells beginning at 30 min after
Fas ligation. An important fraction of cells (z 40%) exhib-
its a disrupted DCm about 2 h after Fas cross-linking, when
DEVDase activity is also significantly augmented. To fur-
ther investigate the relationship between Fas-induced DCm
disruption and activation of CPP32, CEM-C7.H2 cells
were stimulated during 2 h by Fas cross-linking, followed
by staining with the DCm-sensitive dye DiOC6(3) as well
as Annexin V (which measures the aberrant phosphatidyl
serine exposure on the outer plasma membrane leaflet) and
cytofluorometric purification of cells with a still normal
DCm (DiOC6(3)high) as well as cells with a disrupted DCm
(DiOC6(3)low) that are either in an early stage of the apop-
totic process (Annexin V2) or in an advanced stage (An-
nexin V1) (Fig. 1 B). Only DCm
low cells have cleaved the
CPP32 precursor to yield CPP32 fragments (p21 and p17)
and exhibit DEVDase activity (Fig. 1 B). This is observed
for both DCm
low Annexin V2 and DCm
low Annexin V1
cells, indicating that CPP32/DEVDase activation occurs
concomitant with (or shortly after) the DCm disruption. In
contrast,  DCm
high cells behave like unstimulated control
cells and lack any detectable CPP32 cleavage or DEVDase
activation (Fig. 1 B). Thus, CPP32 is only activated in cells
whose DCm is disrupted. Similar results have been obtained
in other models of apoptosis induction, including ceramide-
induced cell death (not shown). As in other models of apop-
tosis induction (4, 6, 9, 12, 31), the Fas-induced DCm col-
lapse precedes nuclear chromatinolysis as identified with
the TUNEL technique (Fig. 1 A). Thus, cells that have dis-
rupted their DCm (CMXRoslow cells) can be subdivided
into TUNEL1 and TUNEL2 populations, whereas
TUNEL1 cells uniformly possess a DCm
low (CMXRoslow)
phenotype (Fig. 1 C). These findings place DCm disruption
upstream of nuclear apoptosis.
ICE-like proteases are involved in both the DCm disrup-
tion and chromatinolysis, because cells treated with the
ICE-specific inhibitor Ac-YVAD.cmk or cells stably trans-
fected with the ICE inhibitor crmA fail to demonstrate mi-
tochondrial or nuclear manifestations of apoptosis in re-
sponse to Fas cross-linking (Fig. 1 C). Thus, in Fas-induced
apoptosis, ICE (or ICE-like proteases) function upstream of
mitochondria. Transfection-enforced hyperexpression of
Bcl-2 does not interfere with Fas-triggered apoptotic
changes, although it does prevent both the DCm dissipation
and DNA loss induced by the apoptosis-inducing second
messenger ceramide (Fig. 1 C). This finding confirms pre-
vious observations that Bcl-2 does not prevent Fas-induced
apoptosis, at least in certain experimental systems (26–28).
Cytosolic ICE-like Proteases Are Necessary to Induce Mito-
chondrial PT. To determine the mechanism by which ac-
tivation of ICE or ICE-like proteases causes DCm disrup-
tion, we incubated isolated hepatocyte mitochondria with
cytosolic extracts from aFas–treated cells. Cytosols from
aFas-treated cells, but not cytosols from sham-treated con-
trol cells, were found to induce large amplitude swelling of
isolated mitochondria (Fig. 2 A), a sign of PT. In addition,
mitochondria treated with cytosols from aFas-treated cells
manifest DCm disruption, another sign of PT (Fig. 2 B).
This PT-inducing activity was maximal in cytosols ob-
tained from cells subjected to Fas cross-linking for 30 min
(not shown), coinciding with the maximum activity of ICE
(-like) proteases (Fig. 1 A). As expected based on the results
in intact cells (Fig. 1 C), transfection with crmA impeded
the cytosolic accumulation of such a PT-inducing activity
(Fig. 2). In addition, the ICE-specific inhibitor Ac-YVAD.
cmk and another inhibitor of ICE, Ac-YVAD.CHO (not
shown), prevented the formation of the PT-inducing activ-
ity in cytosols from aFas-treated cells. Ac-YVAD.cmk also
prevented the action of cytosols that already contained the29 Susin et al.
PT-inducing activity on mitochondria, when added to the
cytosol derived from aFas-treated cells in vitro (Fig. 2). In
contrast, the peptide Ac-DEVD.CHO, an inhibitor of
CPP32, was ineffective (not shown). This suggests that an
ICE-like protease participates in the induction of mito-
chondrial PT, both in cells (Fig. 1 C) and in a cell-free sys-
tem (Fig. 2).
ICE Is Sufficient to Induce Mitochondrial PT In Vitro. In ac-
cordance  with the data obtained with cytosolic extracts,
recombinant purified ICE suffices to induce both large am-
plitude swelling and dissipation of the DCm in isolated mi-
tochondria in vitro (Fig. 3, A and B). This effect of ICE is
rapid (,30 s) and can be neutralized by Ac-YVAD.cmk
and Ac-YVAD.CHO, but not by AcDEVD.CHO, indi-
cating that it relies on the enzymatic activity of ICE. In
contrast, Ac-YVAD.cmk does not interfere with t-BHP-
induced PT, thus excluding that this modified tetrapeptide
might prevent PT in a nonspecific fashion (Fig. 3, A and
B). The use of additional inhibitors underscores the differ-
ent mechanisms involved in ICE– and t-BHP–triggered
PT. For example, cyclosporin A, bongkrekic acid, mono-
chlorobiman (9), and the calpain inhibitor Cbz-LLT. CHN2
(17) all inhibited the t-BHP– but not the ICE–induced PT
in vitro (Table 1). Other proteases besides ICE, such as
trypsin and proteinase K, also induce PT in isolated mito-
chondria (not shown), in accord with previous observations
that microinjection of such proteases induces apoptosis in
cells (40).
Figure 1. Chronology and
cause effect relationship be-
tween activation of ICE (or
ICE-like) protease(s) and DCm
disruption. (A) Chronology of
the activation of ICE, DCm dis-
ruption, and nuclear DNA frag-
mentation in human CEM-
C7.H2 lymphoma cells subjected
to Fas cross-linking. The fre-
quency of DCm
low cells and of
cells exhibiting DNA strand
breaks were determined by dou-
ble staining with the potential-
sensitive dye CMXRos and
TdT-catalyzed FITC-dUTP in-
corporation (TUNEL method),
as described in Materials and
Methods. Note that the
TUNEL1 population is actually
a subset of CMXRoslow cells (see
B). Activation of ICE (-like)
protease(s) was determined by a
fluorogenic substrate containing
the ICE cleavage site YVAD
(filled symbols), the maximum ac-
tivity being defined as 100%.
Similarly, the activation of
CPP32 (-like) protease(s) was
determined by means of a fluo-
rogenic substrate containing the
cleavage site DEVD (open sym-
bols). (B) Temporal relationship
between Fas-induced DCm dis-
ruption and CPP32 cleavage, as
well as DEVDase activation.
CEM-C7.H2 cells were cultured
during 120 min in the presence
of anti-Fas antibody, followed by
staining with the DCm-sensitive
dye DiOC6(3) plus Annexin V (revealed by phycoerythrin). Cells were then separated in the cytofluorometer into cells with a normal DCm
(DiOC6(3)high Annexin V2) or cells with a DiOC6(3)low Annexin V2 or DiOC6(3)low Annexin V1 phenotype (sorting according to Windows), followed
by determination of CPP32 cleavage using Western blots (lane 1, unstimulated control cells; lane 2, nonseparated Fas-stimulated cells; lane 3), purified
DiOC6(3)high cells; lane 4, purified DiOC6(3)low Annexin V2 cells; lane 5, purified DiOC6(3)low Annexin V1 cells, 8 3 105 cells/lane). Alternatively, cy-
tosols from these cell populations were tested for DEVDase activity in vitro as in A (C) Determination of DCm disruption and DNA strand breaks in dif-
ferent cells. CEM-C7.H2 lymphoma cell stably transfected with a Neomycin selection vector (Neo) only (fluorescence displays 1–4), with the crmA
cowpox protease inhibitor (graphs 5 and 6), or with a Bcl-2–expressing construct negatively regulated by doxycyclin (graphs 7–12). Cells were either
pretreated with doxycyclin (10 ng/ml, 48 h before starting of the experiment) to repress Bcl-2 expression (Bcl-22, graphs 7–9) or left untreated (Bcl-21,
graphs 10–12), and then subjected to apoptosis induction with C2 ceramide (50 mM; graphs 9 and 12), anti-Fas (graphs 3, 4, 6, 8, and 11) and/or the
ICE inhibitor Ac-YVAD.cmk (50 mM, all during 4 h; graph 4), followed by double staining with CMXRos and the TUNEL method. Neo control cells
were treated during 15 min with 100 mM of the protonophore mClCCP, providing a negative control for the CMXRos staining (graph 2). Numbers in-
dicate the percentage of cells in each quadrant. Results are representative for three independent experiments.30 Mitochondria and Proteases in Apoptosis
Thus, ICE (or ICE-like) protease(s) is/are necessary and
sufficient to mediate the DCm disruption in cells subjected
to Fas ligation. The mechanism of ICE-induced PT differs
from that of prooxidant-induced PT, suggesting a direct
proteolytic effect of ICE on mitochondria.
ICE Causes the Mitochondrial Release of an Apoptogenic Pro-
tein, AIF. We have previously shown that PT is accom-
panied by the release of an apoptogenic protein that in-
duces isolated nuclei to undergo chromatin condensation
and oligonucleosomal DNA fragmentation (9, 11). Ac-
cordingly, the ICE-induced PT is accompanied by the re-
lease of such an apoptogenic protein (AIF), which causes
purified HeLa nuclei to manifest DNA condensation and
loss of chromosomal DNA (subdiploidy). The ICE inhibi-
tor Ac-YVAD.cmk prevents the ICE-induced mitochon-
drial release of AIF (Fig. 3 C), yet does not interfere with
the activity of AIF itself in the cell-free system of nuclear
apoptosis induction (9, 11, and see below), consistent with
Figure 2. A cytosolic factor
neutralized by ICE-specific pro-
tease inhibitors causes mitochon-
drial PT in vitro. Isolated hepato-
cyte mitochondria were exposed
to cytosols (final concentration:
100  mg/ml protein) prepared from
CEM-C7.H2 lymphoma cells
stably transfected with a Neomy-
cin selection vector (Neo) only
(graphs 1–4) or cells transfected
with the crmA cowpox protease
inhibitor (graphs 5 and 6) that
were either treated with anti-Fas
antibody during 30 min (graphs
2–4, 6) or were left untreated
(graphs 1 and 5). Cytosols were
tested for their capacity to in-
duce mitochondrial swelling,
100% of swelling being defined
as the loss of the OD540 observed
5 min after addition of 5 mM atractyloside (A). Arrows indicate addition of the cytosolic extract. Alternatively, the DCm was assessed cytofluorometri-
cally on a per-mitochondrion basis of mitochondria treated with the indicated cytosol preparation and then stained with the potential-sensitive dye
DiOC6(3) (B). Treatment with the protonophore mClCCP served as a negative control for DiOC6(3) staining (dotted line, graph 1 B). The effect of the
ICE-specific inhibitor Ac-YVAD.cmk was tested in two different ways. Ac-YVAD.cmk was either used with the cells exposed to aFas (Ac-YVAD.cmk1aFas,
graph 3) or, alternatively, was added to the cytosol prepared from Fas-treated cells (aFas1Ac2YVAD.cmk, graph 4).
Figure 3. Recombinant puri-
fied ICE is sufficient to induce
PT, as well as the release of an
apoptosis-inducing factor from
mitochondria. Purified liver mi-
tochondria were treated with CFS
buffer only (graph 1), purified
recombinant human ICE (graphs
2–4), the prooxidant t-BHP
(graphs  5 and 6), and/or differ-
ent protease inhibitors (Ac-
YVAD.cmk, graphs 3 and 6 or
Ac-DEVD.CHO, graph 4). These
reagents were added together to
the mitochondria and the follow-
ing parameters were assessed: large
amplitude swelling (A), DCm
(DiOC6(3) staining, 30 min after
addition of the reagents) (B), and
release of AIF (C). Arrows in A
indicate addition of the indicated
combination of reagents or
buffer only (Control). The dot-
ted line in graph B 1 indicates
the negative control of DiOC6(3)
staining obtained in the pres-
ence of the DCm-dissipating re-
agent mClCCP. For the determination of AIF release (C), mitochondria were centrifuged (1.5 3 1025 g, 1 h) after 5 min of treatment, and the superna-
tant was incubated for 30 min with purified HeLa nuclei, followed by determination of their DNA content using the flurochrome propidium iodide, as
described in Materials and Methods. Percentages detail the percentage of nuclei exhibiting an apparent subdiploidy. 
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the fact that ICE by itself is insufficient to induce apoptosis
in isolated nuclei (38). In conclusion, ICE-induced PT is
accompanied by the release of a mitochondrial apoptogenic
factor.
 
Bcl-2 Overexpression Prevents prooxidant-induced and Ceram-
ide-elicited PT, and Associated Release of AIF, yet Fails to Pre-
vent ICE-induced PT and AIF Release.
 
As outlined in the
Introduction, Bcl-2 is incapable of suppressing the Fas-
induced apoptosis in a number of different models (26–28).
This applies also to CEM-C7-H2 lymphoma cells (Fig. 1
 
C
 
, see above). Since mitochondrial hyperexpression of Bcl-2
prevents the induction of PT by different substances, in-
cluding prooxidants (9, 11; Fig. 4), we tested whether it
would also interfere with ICE-induced PT. Mitochondria
isolated from Bcl-2–transfected cells manifest large ampli-
tude swelling when treated with recombinant ICE, exactly
as do control mitochondria from cells not hyperexpressing
Bcl-2. In addition, Bcl-2 hyperexpression does not prevent
the mitochondrial release of AIF induced by ICE, although
it does suppress the 
 
t
 
-BHP–induced PT and release of AIF
(Fig. 4). This dichotomy in the Bcl-2–mediated regulation
of PT, inhibition of prooxidant-induced PT and failure to
prevent ICE-induced PT, was observed in human CEM-
C7-H2 cells transfected with tetracycline-repressable 
 
bcl-2
 
construct (Fig. 4), as well as in murine 2B4.11 T cell hybri-
doma cell lines stably transfected with the human 
 
bcl-2
 
 gene
(not shown). Thus, Bcl-2 fails to neutralize the effects of
ICE on mitochondria in vitro, consistent with its inability
to prevent ICE-dependent apoptosis in cells. Since Bcl-2
prevents ceramide-induced apoptosis and 
 
DC
 
m
 
 disruption
(Fig. 1 
 
C
 
), we investigated the AIF release of Bcl-2 hyper-
expressing mitochondria treated with cytosolic extracts
from cells that have been treated during a short interval (30
min) with either ceramide or anti-Fas. Control mitochon-
dria readily release AIF upon incubation with such cytosols
(Fig. 5). Bcl-2–hyperexpressing mitochondria demonstrate
a selective protection against yet unidentified ceramide-
elicited PT inducers, yet release AIF upon incubation with
ICE-containing cytosols from anti-Fas–treated cells (Fig.
5). These results are compatible with the hypothesis that
Bcl-2 prevents ceramide-induced apoptosis at the level of
mitochondria.
 
AIF Is an Apoptogenic Protease Which Itself Induces PT.
 
AIF is a preformed 
 
z
 
50-kD intermembrane protein that is
released from mitochondria undergoing PT (11). Isolated
nuclei exposed to AIF exhibit a step-wise alteration in the
morphology of the nucleus which consists in a first step of
chromatin condensation (15 min), followed by disruption
of the nuclear envelope and an associated loss of electron-
 
Table 1.
 
Differential Regulation of ICE- and prooxidant-induced 
Mitochondrial PT
 
Inhibitor of PT
Inhibitory effect on
large amplitude
swelling
 
* 
 
induced by
 
t
 
-BHP ICE
Cyclosporin A (1 
 
m
 
M)
 
12
 
Bongkrekic acid (50 
 
m
 
M)
 
12
 
Monochlorobimane (30 
 
m
 
M)
 
12
 
Chz-LLY.CHN
 
2
 
 (100 
 
m
 
M)
 
12
 
Ac-YVAD.CHO (100 
 
m
 
M)
 
21
 
Ac-DEVD.CHO (100 
 
m
 
M)
 
22
 
z-VAD.fmk (100 
 
m
 
M)
 
21
 
Positive symbols denote significant (
 
.
 
90%) inhibition of large ampli-
tude swelling; negative symbols indicate 
 
,
 
10% inhibition.
 
*
 
Purified mouse hepatocyte mitochondria were tested for the large am-
plitude swelling induced by either ICE (50 
 
m
 
g/ml) and 
 
t
 
-BHP (30 
 
m
 
M)
as in Fig. 3 
 
A
 
. The indicated PT inhibitors were added 15 min before
 
t
 
-BHP or ICE, and the inhibition of large amplitude swelling was de-
termined over a period of 5 min.
Figure 4. Effect of Bcl-2 hyper-
expression on the ICE- or oxi-
dant-induced PT and the release
of an AIF from mitochondria.
Mitochondria were purified
from T cell lymphoma cell lines
stably transfected with a human
bcl-2 gene under the control of a
tetracyclin-repressable promoter
that were treated with doxycy-
clin (10 ng/ml, 48 h) to repress
Bcl-2 expression (Bcl-22, graphs
1–3), or left untreated (Bcl-21,
graphs  4–6). The inset in graph 4
shows cytofluorometric profiles
of isolated mitochondria stained
with an anti–hBcl-2-FITC con-
jugate. These organelles were
exposed to CFS buffer only
(graphs  1 and 4) human recombinant ICE (graphs 2 and 5), or t-BHP (graphs 3 and 6) as described in the legend to Fig. 3, followed by determination of
swelling (A) and the release of AIF (B), which was tested for its capacity to induce hypoploidy in isolated HeLa nuclei. Note that Bcl-2 hyperexpression
on the outer mitochondrial membranes does prevent the t-BHP–induced PT and AIF release, yet does not affect the ICE-induced PT and AIF release.
 32 Mitochondria and Proteases in Apoptosis
dense material (60 min). At this latter stage, nuclei fre-
quently demonstrate two homogeneous zones that differ in
their electron density and resemble nuclei from cells at an
advanced stage of apoptosis (Fig. 6 A). In addition, isolated
nuclei exposed to AIF display two biochemical hallmarks
of apoptosis: (a) loss of total nuclear DNA (hypoploidy)
(11; and Fig. 6 B) and (b) oligonucleosomal DNA fragmen-
tation (11; and Fig. 6 C). The apoptogenic effect of AIF
liberated from ICE-treated mitochondria is neutralized by
the broad spectrum inhibitor of ICE-like proteases Z-VAD.
fmk, but not by the more specific ICE inhibitor Ac-
YVAD.cmk (9, 11; and Fig. 6, B and C), in accord with
the fact that ICE itself is not apoptogenic (38), whereas
ICE-like proteases do have the capacity to provoke nuclear
apoptosis in vitro (41). Since AIF apparently has an ICE-
like catalytic activity (11), we tested whether AIF would
share with ICE the PT-inducing potential. Indeed, the su-
pernatant of ICE-treated mitochondria provokes PT of
freshly isolated mitochondria (Fig. 6 D). This activity is not
neutralized by Ac-YVAD.cmk, yet is completely abolished
by Z-VAD.fmk, suggesting that it is mediated by AIF and
not by residual ICE. Accordingly, AIF enriched on an
anion exchange FPLC column (11) can induce PT in a
Z-VAD.fmk-inhibitable fashion (Fig. 6 D). These data sug-
gest that AIF possesses a biological spectrum of activities
that overlaps, but is not identical, with that of ICE.
AIF Proteolytically Activates CPP32. The proteolytical
activation of CPP32 has been previously shown to be in-
hibited by Z-VAD.fmk (42), which also inhibits the effects
of AIF (11; and Fig. 6). Stimulated by this fact, we have
tested whether mitochondrial intermembrane fractions con-
taining AIF would activate purified recombinant CPP32. As
shown in Fig. 7 A, supernatants of mitochondria induced
to undergo PT in response to Atr (9, 11) indeed activate the
cleavage of a fluorogeneic peptide substrate containing the
CPP32 cleavage site DEVD. This effect is inhibited by
Z-VAD.fmk. Moreover, the same effects were observed
Figure 5. Effect of Bcl-2 on
the AIF release triggered by cy-
tosols from ceramide- or Fas-
stimulated cells. Cytosols (107
cells/100 ml CFS buffer) were
prepared from washed (three
times) cells which were either
left untreated (control) or treated
with C2 ceramide (50 mM) or anti-Fas during 30 min. These cytosols (5
ml) were added to 25 ml CFS buffer only or CFS buffer containing mito-
chondria (50 mg protein) from control CEM-C7-H2 cells (Co. mito) or
from Bcl-2–transfected cells (Bcl-2 mito), followed by an incubation step
of 30 min at 378C. The supernatants of these cultures (14,000 g, 10 min,
48C) were added to purified HeLa nuclei (3 3 104 nuclei in 10 ml CFS
buffer). After 90 min of incubation at 378C, nuclei were stained with PI
and analyzed for the frequency of hypoploid events. One experiment out
of two yielding similar results is shown. Independent control experiments
indicate that C2 ceramide itself does not induce PT in isolated mitochon-
dria at a dose up to 50 mM (not shown).
Figure 6. In vitro effects of
AIF on isolated nuclei and mito-
chondria. (A) Effect of AIF on
nuclear ultrastructure. Isolated
HeLa nuclei were incubated with
purified AIF (100 ng/ml) and/or
the AIF inhibitor Z-VAD.fmk
(100 mM) during the indicated
interval, followed by transmis-
sion electron microscopy. Squares
measure 8 mm. (B and C) ICE
triggers the mitochondrial release
of AIF. Mitochondria were
treated with CFS buffer (Con-
trol, graph and lane 1) or recom-
binant ICE (graphs and lanes 2–4)
in conditions that induce PT
(e.g., Figs. 3 and 4), followed by
recovery of the mitochondrial
supernatant. These supernatants
were then tested for their capac-
ity to induce nuclear apoptosis in
the absence (graph and lane 2) or
presence of 100 mM Ac.YVAD.
cmk (graph and lane 3) or Z-VAD.
fmk (graph and lane 4). The
readout of this system was either
the cytofluorometric detection
of nuclear hypoploidy (B) or
agarose electrophores to detect
oligonucleosomal  DNA fragmen-
tation (C) (D) Effects of AIF on
isolated mitochondria. The same preparations as in B and C (graphs and lanes 1–4); were added to purified liver mitochondria, followed by determina-
tion of large amplitude swelling. In addition, purified recombinant AIF was tested for its capacity to induce mitochondrial swelling (graph 5). AIF was ei-
ther added alone (solid line) or together with 100 mM Z-VAD.fmk (dotted line), as indicated by the arrow.33 Susin et al.
with FPLC-purified AIF (Fig. 7 A). In addition, AIF
(which is by itself incapable of cleaving the “death sub-
strate” PARP) activates CPP32 to digest PARP (Fig. 7 B).
As expected by the finding that AIF activates CPP32,
CPP32 digestion by AIF-containing preparations yields a
21 precursor and a canonical p17 fragment (Fig. 7 C) that
may associate with the p12 fragment to yield a biologically
active heterotetramer (33, 43). This activation does not re-
quire the autocatalytic processing of CPP32, since it is not
inhibited by Ac-DEVD.CHO (Fig. 7 C). In conclusion,
AIF is endowed with the capacity of activating one of the
signature processes of apoptosis, CPP32.
Discussion
The data presented in this work provide multiple novel
connections between proteases and mitochondrial PT dur-
ing the apoptotic effector phase. These interactions are
bidirectional. On the one hand, ICE can provoke mito-
chondrial PT, and, on the other hand, PT entails the mito-
chondrial release of a CPP32-activating protease.
A Novel Pathway of DCm Disruption: Activation of ICE or
ICE-like Proteases. As outlined in the Introduction, DCm
disruption constitutes an early event of apoptosis that pre-
cedes nuclear apoptosis. The apoptotic DCm disruption in-
volves opening PT pores on the inner mitochondrial mem-
brane, based on the observation that PT pore antagonists
such as bongkrekic acid inhibit the apoptotic DCm loss (4,
9, 12). Abundant literature (for review see reference 16) in-
dicates that numerous physiological effectors regulate PT:
concentrations of divalent cations and protons, the redox
status of mitochondrial thiols (in equilibrium with the re-
dox status of glutathione), the redox status of the pyridine
nucleotide pool (NADH2/NAD 1 NADPH2/NADP; ref-
erence 44), concentrations of adenine nucleotides (ADP,
ATP), specific peptides, lipid acid oxidation products (16,
45), and proteases from the calpain family (17). Here we
show that ICE (or ICE-like proteases) contained in the cy-
tosol of Fas-activated cells, as well as recombinant purified
ICE, are capable of inducing a PT-like effect in isolated
mitochondria. ICE induces all three hallmarks of PT: (a)
colloidosmotic swelling (Fig. 3 A), (b) disruption of the
DCm (Fig. 3 B), and (c) release of AIF (Fig. 3 C), which is
self-sufficient to provoke nuclear apoptosis in a cell-free,
cytosol-free system. In contrast with other methods of PT
induction, ICE-mediated PT is not regulated by various
pharmacological inhibitors of PT (e.g., monochlorobiman,
bongkrekic acid; Table 1) and it is not inhibited by overex-
pression of Bcl-2 in the mitochondrial membrane (Fig. 4).
Thus, it appears that the direct proteolytic effect of ICE on
unidentified mitochondrial substrates provoke PT and a
consequent DCm collapse that disrupts mitochondrial func-
tions. The ICE-induced PT is accompanied by AIF release
from mitochondria, similar to PT induced by other com-
pounds including calcium, pro-oxidants, or the thiol–cross-
linking agent diamide (9).
It thus emerges that mitochondria function as a cellular
sensor of stress including changes in redox potentials, direct
oxidative effects, and protease activation. These data sup-
port PT as a candidate for the “central apoptotic execu-
tioner” that has been postulated by several groups (1–5)
and that would allow for the convergence of very different
apoptosis induction pathways into one event downstream
of which would follow the final common pathway of apop-
tosis.
A Novel Effector Protease of Mitochondrial Origin, AIF. Ir-
respective of the PT-triggering stimulus, PT results in the
mitochondrial release of an apoptogenic protease that we
have termed AIF (9, 11). Although the molecular cloning
of cDNA encoding AIF is still in progress, functional tests
performed on purified AIF indicate that it possesses three
unique features. First, AIF is the first protease that has been
shown to suffice in inducing apoptotic changes in isolated
nuclei (9, 11; and Fig. 6, A–C). Thus, at difference with
another mitochondrial product, cytochrome c (10), AIF
Figure 7. AIF proteolytically activates CPP32. (A) Induction of CPP32
activity as determined by a fluorogenic substrate. Variable concentrations
of AIF-containing supernatants (SN) from Atr-treated mitochondria were
added in the presence (open circles) or absence of Z-VAD.fmk (100 mM,
filled circles) to constant amounts (100 ng) of recombinant purified CPP32,
followed by determination of the DEVDase activity of CPP32 using the
fluorogenic substrate Ac-DEVD-amino-4-methylcoumarin. To exclude
that Z-VAD.fmk itself might inhibit the DEVDase activity of CPP32, this
inhibitor was added together with the fluorogenic substrate after CPP32
had been activated with SN in the absence of any inhibitor (open square).
It was also ruled out that the AIF-containing supernatant alone might
contain a DEVDase activity (filled square). Purified AIF (100 ng/ml) was
also used to activate CPP32 (filled triangle). (B) Induction of CPP32 activ-
ity as determined by PARP cleavage. Nuclei were incubated during 90
min at 378C in the presence or absence of CPP32, AIF-containing super-
natant, and/or Z-VAD.fmk, as indicated, followed by Western blotting
and immunochemical determination of the cleavage of PARP. Note that
only the combination of CPP32 and AIF, but not either of these com-
pounds alone, cause PARP cleavage. (C) Proteolysis of CPP32 by AIF.
Recombinant CPP32 protein (10 ng) was exposed to the indicated com-
bination of AIF-containing mitochondrial supernatant (10 mg in 50 ml),
Z-VAD.fmk (100 mM) and/or Ac-DEVD.CHO (100 mM), followed by
Western blot analysis of CPP32 cleavage.34 Mitochondria and Proteases in Apoptosis
does not appear to require the presence of further cytosolic
factors to induce nuclear apoptosis. We cannot exclude the
possibility, however, that purified nuclei are associated with
factors derived from cytosol that are necessary for AIF
function. Second, AIF shares at least one biological effect of
ICE, namely the capacity to trigger PT (Fig. 6 D). Thus,
AIF liberated from mitochondria undergoing PT may en-
gage in a self-amplifying apoptotic switch, and thus aid to
lock the cell in an irreversible stage of apoptosis, beyond
the point of no return. Since the effects of AIF are inhib-
ited by a degenerate tripeptidic inhibitor of ICE and ICE-
like proteases, Z-VAD.fmk (which acts as universal inhibi-
tor of nuclear apoptosis in mammalian cells, perhaps with
the exception of blastomeres; references 46, 47), this may
explain why Z-VAD.fmk can inhibit DCm disruption, at
least in some systems of apoptosis induction (13). Third,
AIF induces cleavage and activation of CPP32 in vitro (Fig.
7). This is a rapid process, with detectable CPP32 cleavage
in as little as 5 min (not shown). CPP32 activation appears
to be a consistent concomitant of the apoptotic process that
may contribute to the apoptotic degradation of different
cellular and nuclear substrates (33, 41, 43), including those
that are not cleaved by AIF such as PARP (Fig. 7 B). This
finding is in accord with the fact that the apoptosis-associ-
ated activation of CPP32 is inhibited by Z-VAD-fmk in
vivo (39, 47). In conclusion, AIF has biological properties
which render it a firm candidate to act as a central molecule
of the apoptotic effector phase.
A Hypothetical Scenario for Fas-induced Apoptosis. When
integrated with the current literature, the data reported in
this work suggest the following scenario for Fas-mediated
apoptosis (Fig. 8). After Fas cross-linking, the Fas receptor
complex rapidly (within seconds) recruits and causes the
proteolytic activation of a protease (pro-FLICE/MACH1/
Mch5/caspase 8; references 20, 21, 48), which indirectly
facilitates the activation of pro-ICE to activate ICE (peak:
z30 min). Thereafter, ICE (or possibly ICE-like proteases)
would cause mitochondrial PT (beginning at z60 min),
which in turn would provoke the liberation of AIF from
the mitochondrial intermembrane space. AIF then acts as
an effector protease or protease activator and activates other
downstream enzymes including CPP32. In this scheme,
FLICE/MACH1 and ICE would act as “initiator” and
“amplifier” proteases (49), within the private initiation phase
of Fas-induced apoptosis. ICE and perhaps other ICE-like
proteases would then induce mitochondrial PT, a process
that causes the release of the “effector” protease/protease
activator AIF from mitochondria, which in turn would
contribute to further induction of mitochondrial PT. In
cells in which Fas-induced apoptosis relies on ICE rather
than on other pathways (e.g., ceramide), Bcl-2 would fail
to impede the ICE-dependent induction of PT. Thus, PT
and associated AIF release would constitute the first event
of the common pathway of apoptosis and the central exe-
cutioner of the effector phase. AIF release then would acti-
vate the “machinery” protease (49) CPP32 and perhaps
other Ced-3–like proteases, which may participate in the
degradation phase of apoptosis.
A possible critique against this sequence of events stems
from the evidence that caspases can activate each other via
direct interactions, at least in vitro (1–3, 5). Moreover, in
some cell-free systems, proteases, in combination with yet
unknown cytosolic factors, can provoke nuclear apoptosis
(FLICE, ICE, CPP32; references 25, 50). Nonetheless, re-
combinant caspases including CPP32 do not induce nu-
clear DNA fragmentation in vitro on their own, in the ab-
sence of additional cytoplasmic extracts (33). Moreover, a
putative direct caspase activation cascade fails to explain
important facts such as the latency between YVADase and
DEVDase activation (z2 h) or the temporal sequence be-
tween YVADase activation, mitochondrial changes plus
CPP32 activation, and late nuclear apoptosis, which is ob-
served in intact cells and is mimicked by our cell-free sys-
tem. In this context, it may be important to note that cyto-
solic extracts from cells which have been treated with
apoptosis inducers (aFas, ceramide) for a short period (30
min) themselves are inefficient inducers to nuclear apopto-
sis in vitro, unless mitochondria are added into the system
(Fig. 5). Thus, the cell-free system that we are using in this
study confirms and extends the notion that mitochondrial
Figure 8. Hypothetical scenario of Fas-induced apoptosis. After trimer-
ization of the Fas receptor and activation of MACH1/FLICE, depending
on the cell type, the ceramide and/or the ICE pathways are activated for
death induction. Bcl-2 is an efficient inhibitor of ceramide- (and prooxi-
dant- ) induced mitochondrial PT, yet fails to prevent the ICE-induced
PT. PT marks the initiation of the common effector phase of apoptosis
and entails the release of mitochondrial intermembrane proteins including
AIF and cytochrome c. AIF itself induces PT and thus engages in a self-
destructive autoamplification loop. AIF alone and cytochrome c in com-
bination with yet unknown cytoplasmic factors are apoptogenic (i.e.,
cause DNA condensation and fragmentation by acting on nuclear sub-
strates). In addition, they trigger the activation of CPP32 (and possibly,
directly or indirectly, of other proteases). For details and references, con-
sult text.35 Susin et al.
products have a major, and perhaps essential, apoptogenic
potential (7–11).
At first glance, our model may appear to be in contradic-
tion with findings reported by Enari et al. (25) who at-
tribute a decisive regulatory role to CPP32 in apoptosis
regulation, based on the fact that preincubation of cells
with the CPP32 inhibitor Ac-DEVD.CHO prevents Fas-
induced apoptosis. However, addition of Ac-DEVD.CHO
to cells after Fas cross-linking has no apoptosis-inhibitory
effect (25), suggesting that Ac-DEVD.CHO acts on up-
stream proteases such as caspase 8, which cleaves the se-
quence motif DEVD (and thus is inhibited by Ac-DEVD.
CHO; Reed, J.C., unpublished observation). Thus, the
temporal and functional analysis of different proteases acti-
vated during Fas-induced apoptosis would suggest that
CPP32 participates in the degradation, rather than in the
execution, phase of apoptosis. Accordingly, addition of
CPP32 inhibitors can suppress detectable DEVDase activa-
tion without affecting the mitochondrial phase of the apop-
totic process (data not shown). As a caveat, this does not
imply that CPP32 (and other closely related Ced-3 homo-
logues) would only participate in the late phase of apopto-
sis. Indeed, it is conceivable that in response to other apop-
tosis inducers (e.g., developmentally programmed cell death),
CPP32 may be involved in an earlier (private) step of the
apoptotic cascade. It has been shown that CPP32 could ac-
tivate unknown cytosolic factors (25) (which likely include
mitochondrial products; reference 10) to become apopto-
genic and thus to induce nuclear apoptosis in a cell-free
system. These data suggest that CPP32 can activate other,
soluble apoptogenic factors.
Irrespective of these possibilities, the results of this work
suggest a unified view of protease-dependent and mito-
chondrial events of the apoptotic cascade. Proteases may
have a major impact on mitochondrial function at the same
time that mitochondria can release proteases and/or pro-
tease activators with apoptosis-inducing properties. The
data reported here, therefore, provide new clues about the
events that trigger the effector phase of apoptosis.
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